Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) just unveiled an update.
On May 14, 2025, Tonix Pharmaceuticals announced the appointment of Joseph Hand as General Counsel and Executive Vice President of Operations, effective immediately. This strategic leadership change is expected to impact the company’s operations and potentially strengthen its industry positioning.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on product development, clinical trials, and regulatory timelines to enhance its market opportunity and competitive position.
Average Trading Volume: 1,306,191
Technical Sentiment Signal: Sell
Current Market Cap: $132M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.